Edwards Lifesciences Corporation is a global leader in heart valve therapies and hemodynamic monitoring. The company's mission is to enhance the quality of life for patients with cardiovascular disease through innovative technologies and solutions. Edwards Lifesciences focuses on research and development to drive advancements in minimally invasive heart valve replacement and repair, as well as critical care monitoring. By collaborating with healthcare professionals and leveraging cutting-edge technology, the company aims to improve patient outcomes and expand access to life-saving treatments worldwide.

EDWARDS LIFESCIENCES CORP

Edwards Lifesciences Corporation (EW) reported impressive fourth-quarter financial results for 2024, showcasing robust performance that outstripped analyst expectations. The company achieved adjusted earnings per share (EPS) of 59 cents, beating consensus estimates of 55 cents, and reflecting a 7.3% increase year-over-year. Sales reached $1.39 billion, marking a 9.4% growth from...

Edwards Lifesciences Reports Strong Q4 Results with Revenue Growth Driven by TAVR and Increased Stock Value Amid Market Challenges